Localization of plasma proteins in the human dental pulp.
Explore the source record for details and available documents.
Adolescent↗
Biomedical subjects
H Honjo
Publications and source records attributed to H Honjo.
Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy.
Thymidine phosphorylase (dThdPase) is reportedly identical to platelet-derived endothelial cell growth factor (PD-ECGF). We conducted immunohistochemical staining of dThdPase to assess correlation between its expression in cancer tissue and efficacy of a combination therapy with 5'-DFUR, radiotherapy and sizofilan (SPG) in uterine cervical cancer patients. No difference in response rates was observed between dThdPase positive and negative tumor and stromal cells. Survival curves significantly differed between stromal dThdPase positive and negative groups (p=0.032). Results showed that dThdPase immunostaining is possibly prognostic and predictive in determining success of the combination therapy.
Adjuvants, Immunologic↗
Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer.
Clinical effects of doxifluridine (group A, 600 mg/body/day; group B, 800 mg/body/day) combined with radiotherapy and immunotherapy were evaluated in patients with advanced cancer of the uterine cervix. Response rates were 84.2% (16/19 patients) in group A and 100% (18/18 patients) in group B, respectively (p=0.230). There was no significant difference in adverse reaction incidence between the methods but significantly higher grade adverse reaction were observed in group B than in group A (p=0.048). Time to progression (TTP) was longer in group B than in group A (p=0.081). The optimal 5'-DFUR dose was 800 mg/body (group B), by which higher grade adverse reactions were fully controlled and TTP was prolonged.
Adult↗
Menopause and hyperlipidemia: pravastatin lowers lipid levels without decreasing endogenous estrogens.
In study 1, serum lipid and estrogen levels were determined in 30 women (aged 40 to > 60 years). Total cholesterol (TC) levels increased significantly with age, but no significant association was found between TC levels and menopausal status. Hypercholesterolemia (TC > 220 mg/dl) was identified in 10 women and hypertriglyceridemia (> 150 mg/dl) in 5 women. Among women not receiving estrogen replacement therapy, a significant negative correlation was found between TC levels and estradiol-17 beta levels. In study 2, serum lipid and estrogen levels were determined in 74 women; 12 of the 74 were receiving conjugated estrogen for the treatment of the menopausal syndrome and 21 hyperlipidemic women were receiving pravastatin (2.5 to 30 mg daily). Among postmenopausal women, high-density lipoprotein cholesterol levels were significantly higher and low-density lipoprotein (LDL) cholesterol levels significantly lower in the estrogen-treated than untreated women. Serum TC and LDL cholesterol levels were significantly reduced during pravastatin treatment. Levels of endogenous estrogens (estradiol-17 beta, estrone, and estrone sulfate) were not significantly affected by pravastatin treatment. The results indicate that pravastatin can be used to reduce hyperlipidemia in menopausal women without affecting endogenous estrogen levels.
Adult↗
Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.
The antitumor effects of pyridoglutethimide (PG; 3-ethyl-3-(4-pyridyl) piperidine -2, 6-dione), a new analogue of aminoglutethimide (AG), were examined in rats with DMBA-induced mammary tumors. On the day following ovariectomy, the DMBA-treated rats were divided into four groups. The rats in each group (n = 25) received testosterone (20 mg/kg/day) or testosterone (20 mg/kg/day) with PG or AG (50 mg/kg/day) daily 6 times per weeks for 4 weeks; tumor volume was measured once weekly. Mammary tumors were dramatically increased after the administration of testosterone. However, in the rats receiving PG or AG simultaneously with testosterone, the tumors were significantly reduced with decrease of serum estradiol levels. Thus PG may suppress the growth of estrogen-dependent mammary tumors.
9,10-Dimethyl-1,2-benzanthracene↗
Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours.
Aromatase cytochrome P-450 was immunohistochemically localised exclusively in the cytoplasm of neoplastic cells of benign and malignant nonfunctional ovarian tumours, whilst (progesterone receptors (PR) and estrogen receptors) (ER) were localised exclusively inn the nuclei of neoplastic cells. Aromatase activity and PR were detected in 68% (17/25) and 32% of the malignant tumours and 82% (22/27) and 67% of the benign tumours, respectively. In postmenopausal tumours, the positivity for PR in malignant tumours was less frequent (p < 0.01) than that in benign tumours. The tumours in which both aromatase and PR were positive, were less frequent (p < 0.05) in malignant than in benign tumours. Aromatase activity was detected in 100% (8/8) of the PR-positive tumours but in only 68% (9/17) of the PR-negative tumours. With postmenopausal malignant tumours, there was a positive correlation between aromatase activity and PR level (r = 0.77, p < 0.001). However, there was no significant difference in the positivity of ER. The serum steroid levels did not correlate with the tumour levels of aromatase activity, PR or ER. These findings suggest that aromatase activity is correlated with PR in ovarian tumours of postmenopausal women. In addition to steroid receptor status, aromatase activity may be a useful factor in ovarian cancer.
Adult↗